StockData
Waters Corp logo

Waters Corp (WAT) KPIs and segments

WATNYSELaboratory Analytical InstrumentsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jul 4, 2026Last filing: 10-Q on Nov 10, 2026Score 9/30456% above fair value
$466.10+16.32 (+3.63%)

Close on Nov 18, 2026Market cap $45.79BP/E 116.2Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Waters · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của Waters: 45 chỉ số vận hành, trong đó có Total Unfulfilled Performance Obligations, Ending Deferred Revenue and Customer Advances Balance và Legacy Deferred Revenue & Customer Advances Maturity, lấy từ 941 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Waters Analytical And Materials Sciences($M)5
756686709609
United States($M)
226204210200
Europe($M)
209207202166
Asia Other($M)
156133145125
China($M)
11810010781
Americas Other($M)
47424537
Waters Advanced Diagnostics($M)5
5213496253
United States($M)
1951211916
Europe($M)
1841322319
Asia Other($M)
554045
Americas Other($M)
473063
China($M)
40261010
Waters Biosciences($M)5
36823200
United States($M)
1499000
Europe($M)
112730
China($M)
482700
Asia Other($M)
332400
Americas Other($M)
261800
Product($M)
1,220919603500473401571462435376541
Consumables($M)
765543165138
Instrument systems($M)
455376308263
Service($M)
425348329300298261302278273261279
Waters Instrument Systems($M)
355282253212341265235191322
Waters Service($M)
299273271237272251246236251
Chemistry consumables($M)
170158165138151139141134143
TA Instrument Systems($M)
78.159.655.650.578.957.858.850.774.8
TA Service($M)
30.326.926.923.929.526.927.124.327.8
United States($M)
570415275245229216263236232203255
Europe($M)
505412316237225185279210197188254
Asia Other($M)
244197168156149130162151137122278
China($M)
2061531161141179111110010085.7108
Americas Other($M)
1209057.347.6514058.043.042.538.348.8
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1
Product($M)
520395363289273232345269259223333
Service($M)
214193207183177153179170161152168
Remaining performance obligations (RPO)($M)
495520267301334340295317337
Total Unfulfilled Performance Obligations (Remaining Performance Obligations)($M)3
617634359392427430332
Expected to Be Recognized Within 1 Year (<=12 Months)($M)
509531280312341349263
Expected to Be Recognized in 13 to 24 Months($M)
70694041.945.942.138
Expected to Be Recognized in 25 Months and Beyond($M)
383438.238.340.639.331.2
Ending Deferred Revenue and Customer Advances Balance($M)3
603592345382421421320358383407324
Beginning Deferred Revenue and Customer Advances Balance($M)
345345320320320324324324
Revenue Recognized from Beginning Deferred Revenue Balance($M)
187195249202125242192104
Net Revenue Deferred During the Period($M)
296323310303226277252188
Legacy Deferred Revenue & Customer Advances Maturity Schedule Total (Through Q3 2024)($M)2
358383407324
Total Point-in-Time Revenue($M)1
1,3401,020715595573482674553527460644
Service Revenue — Time and Materials (Point-in-Time)($M)
12010111194.9100811039192.183.3103
Service & Software Maintenance Contracts Revenue (Over-Time)($M)
305247218205198180199187181177176
Total Disaggregated Net Sales (Note 2)($M)
1,6451,267932800771662873740709637820
Analytical Sciences Division (ASD) Revenue($M)5
703669607649627534
ASD — Instruments Revenue($M)2
282240210257229194
ASD Instruments Reported Revenue Growth (YoY)(%)
9.0%5.0%8.0%
ASD Instruments Constant Currency Revenue Growth (YoY)(%)
10.0%8.0%8.0%
ASD — Service Revenue($M)2
265267253249248216
ASD Service Reported Revenue Growth (YoY)(%)
6.0%8.0%17.0%
ASD Service Constant Currency Revenue Growth (YoY)(%)
8.0%9.0%14.0%
ASD — Chemistry Consumables Revenue($M)2
157162144143150124
ASD Chemistry Reported Revenue Growth (YoY)(%)
10.0%8.0%16.0%
ASD Chemistry Constant Currency Revenue Growth (YoY)(%)
12.0%10.0%13.0%
ASD Reported Revenue Growth (YoY)(%)
8.0%7.0%14.0%
ASD Constant Currency Revenue Growth (YoY)(%)
9.0%9.0%12.0%
Waters Biosciences Division (WBD) Revenue (Comparable Basis)($M)3
396368232387358217
WBD — Flow Cytometry Research Solutions Revenue($M)1
214198131212201122
WBD Flow Research Comparable Revenue Growth (YoY)(%)
1.0%-2.0%7.0%
WBD — Flow Cytometry Clinical Solutions Revenue($M)1
18217010217415795
WBD Flow Clinical Comparable Revenue Growth (YoY)(%)
4.0%8.0%7.0%
WBD Total Comparable Revenue Growth (YoY)(%)
2.0%3.0%7.0%
Advanced Diagnostics Division (ADx) Revenue (Comparable Basis)($M)3
575521349646253
ADx — Acquired Diagnostic Solutions Total Revenue (Comparable Basis)($M)3
500449288498425268
ADx — Microbiology Sub-Unit Revenue (BACTEC, Kiestra, Phoenix, Prepared Media)($M)1
346319203334306185
ADx Microbiology Comparable Revenue Growth (YoY)(%)
4.0%4.0%10.0%
ADx — Molecular Diagnostics (MDx) & Point of Care (PoC) Sub-Unit Revenue($M)1
1541298416411983
ADx Molecular Dx & Point of Care Comparable Revenue Growth (YoY)(%)
-6.0%9.0%2.0%
ADx Diagnostic Solutions Comparable Revenue Growth (YoY)(%)
0.0%5.0%8.0%
ADx — Clinical Business Unit (Organic LC-MS Diagnostics) Revenue($M)2
757261646253
ADx Clinical Business Unit Reported Revenue Growth (YoY)(%)
17.0%15.0%16.0%
ADx Clinical Business Unit Constant Currency Revenue Growth (YoY)(%)
18.0%14.0%14.0%
ADx Total Comparable Revenue Growth (YoY)(%)
2.0%7.0%9.0%
Materials Sciences Division (MSD / TA Instruments) Revenue($M)4
938779878275
MSD — Instruments Revenue($M)2
635952605651
MSD Instruments Reported Revenue Growth (YoY)(%)
6.0%6.0%2.0%
MSD Instruments Constant Currency Revenue Growth (YoY)(%)
8.0%9.0%-2.0%
MSD — Service Revenue($M)2
292927272724
MSD Service Reported Revenue Growth (YoY)(%)
8.0%6.0%13.0%
MSD Service Constant Currency Revenue Growth (YoY)(%)
9.0%7.0%10.0%
MSD Reported Revenue Growth (YoY)(%)
7.0%6.0%6.0%
MSD Constant Currency Revenue Growth (YoY)(%)
9.0%8.0%2.0%
Organic Waters Revenue (Excluding Acquired BDS Business)($M)3
871828747
Organic Reported Revenue Growth (YoY)(%)
9.0%7.0%13.0%
Organic Constant Currency Revenue Growth (YoY)(%)
10.0%9.0%11.0%
Acquired BDS Business Revenue Contribution($M)
896817520
Americas Regional Revenue($M)
749690505332293280256321279275241304
Asia Regional Revenue($M)
495450350284270266221273251237208262
Adjusted Non-GAAP Operating Income($M)7
532462300328243225169309228207172286
Adjusted Non-GAAP Operating Margin(%)
30.1%28.1%23.6%35.2%30.3%29.1%25.5%35.5%30.8%29.2%27.0%34.9%
Adjusted Non-GAAP Gross Profit($M)
985925693
Adjusted Non-GAAP Gross Margin(%)
55.8%56.2%54.7%
Adjusted Non-GAAP Net Income($M)
404301222271203176134244174156131215
Adjusted Non-GAAP Diluted EPS($)
4.103.052.704.533.402.952.254.102.932.632.213.62
Adjusted Free Cash Flow (Non-GAAP)($M)
68202-42160159234
Additions to Property, Plant, Equipment and Software Capitalization($M)
434939252326
U.S. FDA 510(k) Medical Device Clearances (Waters & Acquired BD Diagnostic Systems)
152366331034
Total Inventories($M)3
1,3771,496572573541512477519523539516
Raw Materials Inventory($M)
373373235242236237227241236242234
Work in Progress (WIP) Inventory($M)
1802022833.933.329.821.823.62523.820.2
Finished Goods Inventory($M)
824921309297272245228254262273262
Product Warranty Liability — Ending Balance($M)2
21221211.612121210.510.410.912.1
Warranty Accruals for Warranties Issued During Period($M)
932.601.70213.401.901.400.502.90
Warranty Settlements and Repair Costs Incurred($M)
10421.70212.301.901.801.702
Property, Plant and Equipment, Net2
Depreciation Expense on Property, Plant and Equipment($M)
353621.922.2222222.320.322.222.122.4
Amortization Expense of Purchased Intangible Assets($M)
266171313029282628252625
Operating Lease Right-of-Use (ROU) Assets($M)3
3663568176.479.377.874.276.681.181.184.6
Operating Lease Liabilities — Current($M)
51533128.528.727.325.525.326.426.927.8
Operating Lease Liabilities — Noncurrent($M)
3173025350.552.752.250.353.256.355.958.9
Operating Lease Weighted-Average Discount Rate(%)
4.1%3.8%3.9%4.4%4.2%
Total Global Employees (Headcount)1
Employee Stock Purchase Plan (ESPP) Issuance Value($M)
422.602.80322.402.602.8022.40
Legacy Revenue by Customer Class — Pharmaceutical($M)2
541480462391499430416374464
Pharmaceutical Reported Revenue Growth (YoY)(%)
8.0%12.0%11.0%5.0%8.0%2.0%-3.0%-3.0%-6.0%
Pharmaceutical Constant Currency Revenue Growth (YoY)(%)
7.0%11.0%11.0%8.0%10.0%3.0%-4.0%-6.0%-11.0%
Legacy Revenue by Customer Class — Industrial (Chemical, Materials, Food & Environmental)($M)2
285236238203264228221195260
Industrial Reported Revenue Growth (YoY)(%)
8.0%3.0%7.0%4.0%1.0%9.0%-4.0%-7.0%-3.0%
Industrial Constant Currency Revenue Growth (YoY)(%)
8.0%4.0%6.0%6.0%2.0%7.0%-4.0%-7.0%-4.0%
Legacy Revenue by Customer Class — Academic and Government($M)2
10784.471.767.311082.471.467.395.5
Academic & Government Reported Revenue Growth (YoY)(%)
-2.0%2.0%0.0%0.0%15.0%2.0%-15.0%-25.0%-2.0%
Academic & Government Constant Currency Revenue Growth (YoY)(%)
-3.0%1.0%-3.0%3.0%16.0%0.0%-16.0%-30.0%-9.0%
Legacy Waters Operating Segment Revenue (Through FY2025)($M)2
824713689587764656623562717
Legacy Waters Segment Reported Growth (YoY)(%)
8.0%9.0%11.0%5.0%7.0%4.0%-5.0%-7.0%-5.0%
Legacy Waters Segment Constant Currency Growth (YoY)(%)
7.0%9.0%10.0%8.0%8.0%4.0%-6.0%-10.0%-9.0%
Legacy TA Operating Segment Revenue (Through FY2025)($M)2
10886.582.574.410884.78674.9103
Legacy TA Segment Reported Growth (YoY)(%)
0.0%2.0%-4.0%-1.0%6.0%3.0%-2.0%-9.0%-1.0%
Legacy TA Segment Constant Currency Growth (YoY)(%)
0.0%2.0%-6.0%1.0%7.0%2.0%0.0%-9.0%-2.0%
Legacy Total Recurring Revenue (Service + Chemistry, Through FY2025)($M)2
500458463399453417415395422
Legacy Recurring Revenue Reported Growth (YoY)(%)
10.0%10.0%12.0%1.0%7.0%6.0%4.0%3.0%7.0%
Legacy Recurring Revenue Constant Currency Growth (YoY)(%)
9.0%9.0%11.0%4.0%9.0%7.0%5.0%3.0%5.0%
Legacy Single-Segment Significant Expenses — Labor in S&A and R&D (ASU 2023-07, Through FY2025)($M)3
164164164152152144147154
Legacy Single-Segment — Material Purchases in Cost of Sales($M)
189135113102187135126109
Legacy Single-Segment — Labor Costs in Cost of Sales($M)
10310096.288.491.188.185.486.4
Legacy Single-Segment — Other Segment Expenses($M)
206208209168150162162155
Consolidated Net Sales (GAAP)($M)11
1,6451,267932800771662873740709637820
Cost of Product Sales (GAAP)($M)
700524241211200169226193176153207
Cost of Service Sales (GAAP)($M)
211155122117121108123108112109111
Selling and Administrative Expenses (GAAP)($M)
405387240214198174173169173175180
Research and Development Expenses (GAAP)($M)
1229646.953.6494746.945.346.244.644.4
Consolidated Operating Income (GAAP)($M)
-86-47271192188152292211189134264
Interest Expense (GAAP)($M)
604814.326.615141921.423.725.530.7
Income Before Income Taxes (GAAP)($M)
-141-88264170178143277194169115238
Provision for Income Taxes (GAAP)($M)
-5-163921.2312245.632.126.712.721.4
Consolidated Net Income (GAAP)($M)
-136-72225149147121231162143102
GAAP Diluted EPS($)
-1.39-0.873.772.502.472.033.882.712.401.723.65
Weighted-Average Diluted Shares Outstanding(M)
98,204,00082,139,00059,76359,62259,656,00059,711,00059,64559,50459,45159,43159,311
Geographic Net Sales — United States($M)2
570415275245229216263236232203255
Geographic Net Sales — Total Americas($M)
690505332293280256321279275241304
Geographic Net Sales — Total Asia($M)
450350284270266221273251237208262
Total Assets (GAAP)($M)8
24,75124,5315,0774,8634,7184,5924,5544,5124,4494,5094,627
Cash and Cash Equivalents($M)
539462588459367383325331326337395
Accounts Receivable, Net($M)
1,987673829749730713733670610626702
Inventories (Balance Sheet)($M)
1,3771,496572573541512477519523539516
Property, Plant and Equipment, Net (Balance Sheet)($M)
1,4891,520642637645643651643636634639
Goodwill($M)
9,4219,3171,3401,3381,3381,3001,2961,3071,2981,2981,305
Purchased Intangible Assets, Net($M)
8,5218,776558571579561568592596611629
Total Liabilities($M)
9,5569,2392,5152,5322,5582,6292,7252,9093,0373,2523,477
Total Stockholders' Equity($M)
15,19515,2922,5622,3312,1601,9621,8291,6031,4121,2571,150
Net Cash Provided by Operating Activities (GAAP)($M)2
201-31651874126024020554.5263230
Stock-Based Compensation Expense($M)
252014.513.6131311.710.611.410.94.60
Repurchases of Common Stock($M)
2120.100.50-0140.100.100.2013.1-0.20

1 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Core Operational KPIs (Groups 1-3): Unfulfilled Performance Obligations (contract backlog by maturity horizon: <=12 months, 13-24 months, 25+ months) and Deferred Revenue Rollforward from Note 2; ASC 606 Revenue by Recognition Timing (Point-in-Time Instruments, Chemistry Consumables, and Time-and-Materials Service vs. Over-Time Service & Software Maintenance Contracts); and Post-Merger Sub-Division Revenue across Analytical Sciences (ASD), Biosciences (WBD Flow Research & Flow Clinical), Advanced Diagnostics (ADx Microbiology, Molecular Dx & PoC, and Clinical Business Unit), and Materials Sciences (MSD).
  • Period Derivations: Flow metrics disclosed for three-month Q1-Q3 and cumulative 6M/9M in Form 10-Q alongside full-year figures in Form 10-K (Point-in-Time vs. Over-Time revenue disaggregation, ASU 2023-07 significant segment expenses, warranty accruals/settlements, depreciation, intangible amortization, and GAAP cash flows) include derived Q4 = full year (10-K) − nine months (10-Q) and Q2/Q3 = YTD − prior YTD.
  • February 9, 2026 BDS Merger & Segment Reorganization: On February 9, 2026 (Q1 2026), Waters completed the Reverse Morris Trust acquisition of Becton, Dickinson and Company's Biosciences & Diagnostic Solutions (BDS) business and reorganized its reporting into four operating divisions (ASD, WBD, ADx, MSD). Standalone audited financials of the acquired BDS business (FY2023-FY2025) are presented in Group 7, and pre-merger legacy series (Waters vs. TA divisions and Pharmaceutical/Industrial/Academic customer classes through FY2025) are preserved in Group 8.
  • Q3 2026 vs. Q2 2026 Reporting Cadence: Form 8-K Q3 2026 earnings release, Q3 2026 investor presentation, and openFDA 510(k) clearances are reported through Q3 2026 (ended September 27, 2026), while Form 10-Q footnote schedules (Note 2 RPO, deferred revenue rollforward, recognition timing, inventories by stage, and warranty rollforward) are reported through Q2 2026.

Không hiện vì thiếu các kỳ gần đây (18)

  • Ending Deferred Revenue and Customer Advances Balance › Deferred Revenue Acquired in Business Combinations
  • Analytical Sciences Division (ASD) Revenue › ASD — Pharmaceutical Customer Revenue
  • Analytical Sciences Division (ASD) Revenue › ASD — Non-Pharmaceutical Customer Revenue
  • Organic Waters Revenue (Excluding Acquired BDS Business) › Acquired BDS Business Comparable Revenue Growth (YoY)
  • GLP-1 Testing Incremental Revenue
  • PFAS Testing Incremental Revenue
  • India Generics Incremental Revenue
  • Total Scope 1 & 2 Greenhouse Gas Emissions (ktCO2e)
  • Total Energy Consumption (MWh)
  • Municipal Water Withdrawal (Cubic Meters)
  • Total Operational Waste Generated (Metric Tons)
  • Total Recordable Incident Rate (TRIR per 100 FTE)
  • Consolidated Net Sales (GAAP) › Consolidated Cost of Sales (GAAP)
  • Consolidated Net Sales (GAAP) › Consolidated Gross Profit (GAAP)
  • Geographic Net Sales — United States › Geographic Net Sales — Japan (Discontinued Separate Disclosure After Q1 2024)
  • Net Cash Provided by Operating Activities (GAAP) › Capital Expenditures (PP&E and Software)
  • Note 13 Analytical & Materials Sciences — China Revenue
  • Note 13 Reportable Segments — Material Purchases

Dữ liệu cập nhật 2026-11-08.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Waters

See a number that looks wrong?